Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female at least 18 years of age~* Must have gastric cancer or gastroesophageal junction cancer that cannot be operated on and that is advanced or has spread out~* Did not receive neoadjuvant or adjuvant treatment (chemotherapy, radiotherapy, or both) for their disease within the last 6 months~* Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work~* Must agree to provide tumor tissue sample, either from a previous surgery or biopsy within 6 months or fresh, prior to the start of treatment in this study~Exclusion Criteria:~* Presence of tumor cells in the brain or spinal cord that have not been treated~* Active known or suspected autoimmune disease~* Any serious or uncontrolled medical disorder or active infection~* Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)~* Any positive test result for hepatitis B or C indicating acute or chronic infection~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy~Enrollment is closed for this arm
- XELOX (Oxaliplatin + Capecitabine) (Type: ACTIVE_COMPARATOR): None
- FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil) (Type: ACTIVE_COMPARATOR): None
- Nivolumab + XELOX (Type: EXPERIMENTAL): None
- Nivolumab + FOLFOX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).